[HTML][HTML] Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: rationale and design of …
K Okumura, GYH Lip, M Akao, K Tanizawa… - American Heart …, 2017 - Elsevier
Edoxaban—a non–vitamin K antagonist oral anticoagulant (NOAC)—60-mg and 30-mg
once-daily dose regimens are noninferior versus well-managed warfarin for the prevention …
once-daily dose regimens are noninferior versus well-managed warfarin for the prevention …
[引用][C] Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of …
K Okumura, GYH Lip, M Akao, K Tanizawa… - American Heart …, 2017 - cir.nii.ac.jp
Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for
standard oral anticoagulant therapies: Rationale and design of the ELDERCARE-AF study …
standard oral anticoagulant therapies: Rationale and design of the ELDERCARE-AF study …
Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the …
K Okumura, GYH Lip, M Akao, K Tanizawa… - American Heart …, 2017 - vbn.aau.dk
Edoxaban-a non-vitamin K antagonist oral anticoagulant (NOAC)-60-mg and 30-mg once-
daily dose regimens are noninferior versus well-managed warfarin for the prevention of …
daily dose regimens are noninferior versus well-managed warfarin for the prevention of …
Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the …
K Okumura, GYH Lip, M Akao, K Tanizawa… - American Heart …, 2017 - europepmc.org
Edoxaban-a non-vitamin K antagonist oral anticoagulant (NOAC)-60-mg and 30-mg once-
daily dose regimens are noninferior versus well-managed warfarin for the prevention of …
daily dose regimens are noninferior versus well-managed warfarin for the prevention of …
Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the …
K Okumura, GYH Lip, M Akao… - American heart …, 2017 - pubmed.ncbi.nlm.nih.gov
Edoxaban-a non-vitamin K antagonist oral anticoagulant (NOAC)-60-mg and 30-mg once-
daily dose regimens are noninferior versus well-managed warfarin for the prevention of …
daily dose regimens are noninferior versus well-managed warfarin for the prevention of …
Edoxaban for the Management of Elderly Japanese Patients with Atrial Fibrillation Ineligible for Standard Oral Anticoagulant Therapies:: Rationale and Design of the …
K Okumura, G Lip, M Akao… - American Heart …, 2017 - research.birmingham.ac.uk
Edoxaban—a nonvitamin K antagonist oral anticoagulant (NOAC)—60-mg and 30-mg once-
daily dose regimens are noninferior vs well-managed warfarin for the prevention of stroke or …
daily dose regimens are noninferior vs well-managed warfarin for the prevention of stroke or …
[PDF][PDF] Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of …
K Okumura, GYH Lipb, MAKTM Fukuzawae, K Abef… - 2017 - scholar.archive.org
Objectives and study design The primary objective of this study is to evaluate the efficacy
and safety of once-daily edoxaban 15 mg in patients with nonvalvular AF who are ineligible …
and safety of once-daily edoxaban 15 mg in patients with nonvalvular AF who are ineligible …
[PDF][PDF] Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of …
K Okumura, GYH Lipb, MAKTM Fukuzawae, K Abef… - 2017 - vbn.aau.dk
Objectives and study design The primary objective of this study is to evaluate the efficacy
and safety of once-daily edoxaban 15 mg in patients with nonvalvular AF who are ineligible …
and safety of once-daily edoxaban 15 mg in patients with nonvalvular AF who are ineligible …